Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045257 | 0.89 | SLC6A3 (0.38) | NPC1GALR3NR2F2RAB9ANOS1 | |
| SCHEMBL20667986 | 0.86 | TLR8 (0.41) | — | |
| SCHEMBL31045102 | 0.86 | SLC6A3 (0.40) | NPC1GALR3NR2F2RAB9ASLC6A3 | |
| SCHEMBL31045304 | 0.86 | TAAR1 (0.38) | NPC1GALR3NR2F2RAB9AKDM4E | |
| SCHEMBL31045132 | 0.85 | MAPK14 (0.40) | NPC1GALR3NR2F2RAB9AKDM4E | |
| SCHEMBL31044982 | 0.84 | ADRA2C (0.43) | NPC1GALR3NR2F2RAB9ASLC6A3 | |
| SCHEMBL31044731 | 0.83 | TLR8 (0.43) | — | |
| SCHEMBL31045022 | 0.82 | NPC1 (0.39) | NPC1GALR3NR2F2RAB9AKDM4E | |
| SCHEMBL31045439 | 0.82 | NPC1 (0.40) | NPC1GALR3NR2F2RAB9AKDM4E | |
| SCHEMBL31044699 | 0.80 | NPC1 (0.39) | NPC1GALR3NR2F2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | FIMBRION THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279236-A1 | COMPOUNDS AND METHODS OF TREATING TUBERCULOSIS | G6PD, SDHA, NQO1 | NPC1 626/4885GALR3 4159/4885NR2F2 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.